This clinical trial is focused on studying a condition called chronic graft versus host disease (cGVHD). This condition can occur after a person receives a stem cell or bone marrow transplant, where the donated cells attack the recipient’s body. The study is testing a new oral medication called belumosudil, which is being used in combination with corticosteroids, a type of medication that helps reduce inflammation and suppress the immune system. The trial will compare the effects of belumosudil combined with corticosteroids against a placebo combined with corticosteroids.

The purpose of the study is to see if belumosudil, when used with corticosteroids, is more effective than corticosteroids alone in improving the condition of patients with newly diagnosed cGVHD. Participants in the study will be randomly assigned to receive either the combination of belumosudil and corticosteroids or a placebo and corticosteroids. The study will monitor participants over a period to assess their health and any changes in their condition.

Throughout the study, participants will take the medication orally, and their progress will be closely observed by the research team. The trial aims to provide valuable information on the safety and effectiveness of belumosudil in treating cGVHD, potentially offering a new treatment option for those affected by this condition.